Overview

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine if Exendin-(9-39), an antagonist of the glucagon-like peptide-1 (GLP-1) receptor with effects on the pancreatic beta cell, increases fasting blood glucose levels in subjects with congenital hyperinsulinism.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Diva De Leon
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
Treatments:
Glucagon-Like Peptide 1
Criteria
Inclusion Criteria:

- Subjects with congenital hyperinsulinism

Exclusion Criteria:

- Acute medical illness

- History of other systemic chronic disease such as cardiac failure, renal
insufficiency, hepatic insufficiency, chronic obstructive pulmonary disease, anemia,
or uncontrolled hypertension

- Pregnancy

- Diabetes mellitus

- Use of medications that affect glucose metabolism, such as glucocorticoids, beta
agonists, diazoxide and octreotide.

- Subjects will be eligible to participate 48 hrs after the last dose of octreotide and
72 hrs after last dose of diazoxide